Susan Kanaya Net Worth

The estimated Net Worth of Susan M Kanaya is at least $7.37 millió dollars as of 16 August 2022. Ms. Kanaya owns over 19,898 units of ChemoCentryx Inc stock worth over $5,782,068 and over the last 13 years she sold CCXI stock worth over $0. In addition, she makes $1,584,360 as Chief Financial Officer, Executive Vice President, Chief Administrative Officer és Secretary at ChemoCentryx Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Kanaya CCXI stock SEC Form 4 insiders trading

Susan has made over 46 trades of the ChemoCentryx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently she exercised 19,898 units of CCXI stock worth $216,092 on 16 August 2022.

The largest trade she's ever made was exercising 311,625 units of ChemoCentryx Inc stock on 26 November 2019 worth over $2,147,096. On average, Susan trades about 28,137 units every 60 days since 2012. As of 16 August 2022 she still owns at least 111,215 units of ChemoCentryx Inc stock.

You can see the complete history of Ms. Kanaya stock trades at the bottom of the page.

Susan Kanaya biography

Susan M. Kanaya serves as Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary of the Company. Since February 2006. From January 2006 to October 2016, Ms. Kanaya served as our Senior Vice President, Finance, and Chief Financial Officer. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.

What is the salary of Susan Kanaya?

As the Chief Financial Officer, Executive Vice President, Chief Administrative Officer és Secretary of ChemoCentryx Inc, the total compensation of Susan Kanaya at ChemoCentryx Inc is $1,584,360. There are 1 executives at ChemoCentryx Inc getting paid more, with Thomas Schall having the highest compensation of $3,341,860.

How old is Susan Kanaya?

Susan Kanaya is 58, she's been the Chief Financial Officer, Executive Vice President, Chief Administrative Officer és Secretary of ChemoCentryx Inc since 2017. There are 8 older and 4 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.

What's Susan Kanaya's mailing address?

Susan's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 835 INDUSTRIAL ROAD, SUITE 600, SAN CARLOS, CA, 94070.

Insiders trading at ChemoCentryx Inc

Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta és (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.

What does ChemoCentryx Inc do?

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Complete history of Ms. Kanaya stock trades at ChemoCentryx Inc

ChemoCentryx Inc executives and stock owners

ChemoCentryx Inc executives and other stock owners filed with the SEC include:

• Thomas Schall,
  Chairman of the Board, President, Chief Executive Officer
• Susan Kanaya,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary
• Markus Cappel,
  Chief Business Officer, Treasurer
• Dr. Thomas J. Schall Ph.D.,
  Founder, Pres, CEO & Chairman
• Susan M. Kanaya,
  Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
• Dr. Markus J. Cappel Ph.D.,
  Sr. VP, Chief Bus. Officer & Treasurer
• Rita Jain,
  Independent Director
• James Tyree,
  Independent Director
• Henry McKinnell,
  Independent Director
• Thomas Edwards,
  Independent Director
• Joseph Feczko,
  Independent Director
• Geoffrey Parker,
  Independent Director
• Dr. Rita I. Jain M.D.,
  Exec. VP, Chief Medical Officer & Exec. Employee Director
• Dr. Sangita Ghosh Ph.D.,
  Sr. VP of Technical Operations
• Dalia R. Rayes,
  Sr. VP & Head of Commercial
• Kari E. Leetch,
  Sr. VP of HR
• Tausif Butt,
  Exec. VP & COO
• Roger C Lucas,
  Director
• Petrus Bekker,
  SVP of Medical & Clinical
• Rajinder Singh,
  SVP, Research
• Partners L P/Ilbiotechnolog...,
  
• Jennifer Lyn Herron,
  Director
• Pui San Kwan,
  Principal Acctg Officer
• William Fairey,
  Chief Operating Officer
• Plc Gsk,
  10% owner
• Edward Penhoet,
  Director
• Ira Klein,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Anne Marie Duliege,
  EVP, Chief of Strategic Dev.
• Israel Charo,
  SVP, Research
• Juan C. Jaen,
  SVP, Drug Discovery & CSO
• Tausif Butt,
  EVP, Chief Operating Officer
• Partners L P/Ilbvf Investme...,
  
• Corp /Mn/ Techne,
  10% owner
• Advisors Llcorbimed Capital...,
  
• Rishi Gupta,
  Director
• (International) Ltd Vifor P...,
  
• Yi Ching Yau,
  SVP, Finance & Acctg Officer
• David E. Wheadon,
  Director